GlobeNewsWire
06 Dec 2025, 14:30 UTC · 41w ago
Verdict
Headline takes no side. We score GMAB +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Genmab reported an overall response rate (ORR) of 98% and a 3-year overall survival rate of 83% for epcoritamab plus R-CHOP in newly-diagnosed DLBCL patients with poor prognoses.
More positive than 99% of claims this week
Epcoritamab monotherapy achieved a 73% ORR in elderly DLBCL patients unable to receive standard chemotherapy.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 92% of claims this week
The EPCORE NHL-2 trial showed a three-year overall survival rate of 96% for patients with follicular lymphoma (FL) following first-line combination treatment.
More positive than 85% of claims this week
Trial data showed Grade ≥3 infections in 32% of patients in the R-mini-CHOP arm, with some treatment discontinuations due to adverse events.
More negative than 71% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company announced highly positive clinical trial results showing high overall response rates and survival for its drug epcoritamab.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
46m ago
+9.1%
Price agrees with the score
$34.63 vs $31.74 close before publication (Dec 5) · not market-adjusted
GMAB chart →
